Last reviewed · How we verify

Mepha Ltd. — Portfolio Competitive Intelligence Brief

Mepha Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
artesunate and mefloquine artesunate and mefloquine marketed Antimalarial combination Plasmodium falciparum heme iron (artesunate); parasite digestive vacuole and mitochondria (mefloquine) Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Armed Forces Research Institute of Medical Sciences, Thailand · 1 shared drug class
  2. Centers for Disease Control and Prevention · 1 shared drug class
  3. Centre for Global Health Research, Ghana · 1 shared drug class
  4. Charite University, Berlin, Germany · 1 shared drug class
  5. Epicentre · 1 shared drug class
  6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 shared drug class
  7. GlaxoSmithKline · 1 shared drug class
  8. Albert Schweitzer Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mepha Ltd.:

Cite this brief

Drug Landscape (2026). Mepha Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mepha-ltd. Accessed 2026-05-14.

Related